Medicare GLP-1 Coverage Goes Live: What 7 Million Seniors Need to Know

Beginning January 1, 2027, Medicare Part D will cover anti-obesity medications for the first time in the program's history—a provision of the Inflation Reduction Act that CMS projects will benefit approximately 7 million eligible seniors.

What Is Covered

Medicare's negotiated coverage includes semaglutide (Wegovy) at $274/month for enrollees with BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea). Tirzepatide coverage and pricing are expected to be finalized by Q3 2026.

Prior Authorization Requirements

CMS has allowed individual Part D plans to impose prior authorization requirements, which vary significantly. Most plans are expected to require documentation of BMI, at least one failed dietary intervention, and physician attestation of medical necessity. Processing times range from 48 hours to two weeks.

The Scale of Impact

CMS estimates 3.4 million new prescriptions in the first year of coverage—representing the largest single expansion of obesity pharmacotherapy in American history. The downstream effects on Medicare spending are debated: while medication costs will increase, advocates argue reduced hospitalizations for obesity-related conditions (heart disease, diabetes, joint replacements) will offset costs within 3–5 years.

What Seniors Should Do Now

• Confirm your Part D plan covers GLP-1 medications in the 2027 formulary (open enrollment: Oct 15–Dec 7, 2026)
• Discuss eligibility with your physician and begin documentation
• Understand that medication alone produces suboptimal outcomes—seek comprehensive care including lab monitoring, nutrition guidance, and exercise protocols